Hemab Therapeutics

Hemab Therapeutics Hemab partners with patients, HCPs, advocacy organizations, and scientists to raise awareness of rare bleeding disorders. Learn more at www.hemab.com.

Overview
In partnership with patients, healthcare professionals, and scientists, Hemab is raising awareness about rare bleeding and clotting disorders, while urgently working to develop better treatment options. Based in Cambridge, Massachusetts, and Copenhagen, Denmark, Hemab is focused on transforming the standard of care for patients with these serious, underserved conditions. The company is ad

vancing a pipeline of innovative therapeutics aimed at addressing high unmet needs in blood clotting disorders like Glanzmann Thrombasthenia (GT), factor VII deficiency, Bernard-Soulier Syndrome, and Von Willebrand Disease. Clinical Trials
At Hemab, we are dedicated to advancing treatments for rare bleeding disorders. We are actively enrolling in a Phase 2 clinical trial of HMB-001, a subcutaneous injection designed to restore clot formation impaired by GT. The study seeks volunteers aged 18 to 65 with a confirmed or suspected diagnosis of GT to evaluate HMB-001’s potential to reduce bleeds. To learn more or enroll, contact [email protected] or visit https://clinicaltrials.gov/study/NCT06211634

What an incredible morning! Stepping up to the Nasdaq podium today as COAG is a feeling we won't soon forget.The opening...
05/06/2026

What an incredible morning! Stepping up to the Nasdaq podium today as COAG is a feeling we won't soon forget.

The opening bell is another call to advance treatments for underserved blood coagulation disorders.

Today is entirely about accelerating our ability to build for the patients who urgently need better options. Thank you to everyone working alongside us to make it happen.

05/01/2026

Every step we take at Hemab is driven by a single purpose: reaching the overlooked patients who have been waiting decades for better blood coagulation treatments.

Today as we are officially a Nasdaq-listed company (COAG), it isn't about celebrating a corporate victory, it's about fueling the hard work ahead to bring those much-needed treatments to life.

We share this day with the dedicated employees, partners, stakeholders and patient community members working alongside us to make meaningful progress towards treatments.

Read more: https://ir.hemab.com/news-releases/news-release-details/hemab-therapeutics-announces-pricing-upsized-initial-public

04/08/2026

Horizon blindness is what happens when patients stop expecting better: a rational response when nothing better has been offered.

GT360, VWD360, and FVIID360 – our natural history studies – were designed to ask the questions that have historically gone unasked. The lived experiences reshaped how we think about disease burden: in GT360, 88% of participants had bled in the past week and approximately 30% met criteria for symptomatic depression. And across the board, quality of life was further driven down by anxiety.

Patient voices make better therapies possible, and our natural history studies are where it all begins. At Hemab, we’re working toward a future where the horizon feels visible again: https://www.hemab.com/about-us -approach

Iron deficiency and iron deficiency anemia disproportionately affect Black women of reproductive age — with prevalence r...
04/07/2026

Iron deficiency and iron deficiency anemia disproportionately affect Black women of reproductive age — with prevalence rates up to five times higher than the general female population.

They're told their periods are "just heavy." They research and buy iron supplements. They schedule their lives around heavy bleeding episodes that never got diagnosed.

When an underserved bleeding disorder presents as a common symptom, it gets normalized. When it's normalized in a community already facing diagnostic delays, our ability to close gaps in health equity disappears entirely.

April is National Minority Health Month. This week is Black Maternal Health Week. Both exist because the same women keep falling through the same gaps. And today, World Health Day, is a reminder that bleeding disorders drive global health burdens like iron deficiency and anemia and these remain largely unrecognized.

For a healthier world tomorrow, recognizing the overlooked and getting to a diagnosis of bleeding disorders is a critical first step.

03/30/2026

Clinicians see patients for minutes. Patients live with their condition for a lifetime.

Natural history studies reveal what patients experience every day – beyond the clinic walls and beyond horizon blindness, where patients stop asking for more because they’ve been told nothing exists.

Sharing your lived experience helps researchers see the full impact of bleeding disorders and shapes the development of better treatments.

VELORA Discover, a screening study of bleeding and treatment in people living with Von Willebrand disease (VWD), has already helped redefine our understanding of Type 1 VWD, and by contributing your story, you can help continue to shape research and care.

Learn more and join at https://hemab.typeform.com/contact

03/26/2026

Underserved bleeding disorders are finally in focus, but treating them still requires looking at the full picture.

Factor VII deficiency (FVIID) is a rare, inherited bleeding disorder caused by low levels of factor VII, a protein essential for initiating blood clotting.

People living with FVIID experience spontaneous to life-threatening bleeds. But understanding FVIID means looking beyond bleed rates to the lived experiences.

The FVIID360 natural history study sheds light on both the clinical experience of bleeding and the psychosocial burden of living with a chronic condition, highlighting under‑use of prophylaxis and the strong social and emotional impact on patients – including pain, limits on activity, lost work or education, and feelings of isolation, even when factor levels appear mild.

Throughout Bleeding Disorders Awareness Month, we’re calling attention to both the disease landscape and patients’ lived experience to drive progress for conditions too often overlooked.

Team Hemab had an incredible time at the THSNA Summit in Portland, presenting insights on HMB-002, connecting with the t...
03/25/2026

Team Hemab had an incredible time at the THSNA Summit in Portland, presenting insights on HMB-002, connecting with the thrombosis and hemostasis community, and learning from the latest research in bleeding and clotting disorders.

A highlight of the event was meeting with our Von Willebrand Disease Investigators, where we engaged, exchanged ideas, and strengthened collaborations that advance care for patients.

Thank you to everyone who joined us. Together, we’re driving progress in underserved bleeding and clotting disorders.

03/18/2026

💬 “I never met someone with Glanzmann thrombasthenia before…”

At Hemab, we’re connecting people with Glanzmann thrombasthenia (GT) worldwide by partnering with Sano Genetics on the Global Voices of GT survey.

Share your story, meet others who understand, and be the first to hear about future events and initiatives:

We’re heading to THSNA 2026!Every milestone in our science starts with a conversation, whether with a lived experience e...
03/17/2026

We’re heading to THSNA 2026!

Every milestone in our science starts with a conversation, whether with a lived experience expert, clinician, or a researcher who refuses to accept the status quo in overlooked bleeding disorders. Portland is where those conversations continue.

Don’t miss our March 21st oral presentation for the latest on HMB-002, our investigational backbone therapy for the prophylactic treatment of Von Willebrand disease (VWD).

Interested in meeting about VWD, Glanzmann thrombasthenia, Factor VII deficiency, or other earlier-stage programs? Send a DM or leave a comment below!

Address

101 Main Street
Cambridge, MA
02142

Website

Alerts

Be the first to know and let us send you an email when Hemab Therapeutics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Hemab Therapeutics:

Shortcuts

Share

Category